MaxHealth Medicine Group

Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.